🔬 Sometimes, the biggest breakthroughs in AI begin with better ways of observing biology.
- Jul 5
- 1 min read
A recent breakthrough from researchers at Biohub and UC Berkeley demonstrates exactly that.
Their development of a laser phase plate significantly enhances the contrast of cryo-electron microscopy (cryo-EM), allowing scientists to visualize proteins and cellular structures that were previously difficult—or even impossible—to observe.
Why does this matter beyond microscopy?
Because every advancement in biological measurement improves the quality of the data we generate.
And in the era of AI-driven drug discovery, better data leads to better models.
For years, AI has been transforming how we analyze biological information. But the performance of any AI system ultimately depends on the quality of the biological data it learns from. Higher-resolution structural data enables researchers to better understand protein conformations, molecular interactions, and disease mechanisms—creating richer datasets for computational biology and machine learning.
This is one reason why structural biology is becoming a cornerstone of next-generation drug discovery.
For companies like AlgorithmicRx, focused on AI-powered drug discovery for rare diseases, innovations across the biological research ecosystem are incredibly exciting. Advances in imaging, multi-omics, structural biology, and AI are not isolated developments—they are complementary technologies that strengthen one another.
As these fields continue to converge, we move closer to building AI systems that are not only computationally powerful but also deeply informed by biology.
Better biology → Better data → Better AI → Better medicines.
That's the future we're excited to help build.
What recent advances in biological measurement or structural biology do you think will have the greatest impact on AI-driven drug discovery?
Comments